Thanks for sharing. pinch. Back in Nov '22, this 3rd Gen CAR-T was still in the lab but hopeful of being progressed into the clinic. And, here we are heading into the clinic with 3 trials investigating CDH17 and ongoing pre-clinical studies into other solid cancers expressing CDH17.
I think Dr Hua states 100% of GI NETs (Gastrointestinal Neuroendocrine Tumors) express CDH17 in his presentation. Does this suggest that CDH17 could be a target expressed on neuroendocrine cells manifesting as tumours elsewhere in the body?
https://www.pennmedicine.org/news/news-releases/2022/march/penn-developed-car-t-cells-suppress-gi-solid-tumor-cells-without-toxicity-to-healthy-tissue
https://www.pennmedicine.org/cancer/types-of-cancer/neuroendocrine-tumors/types-of-neuroendocrine-tumors/gastrointestinal-neuroendocrine-tumors
Thanks for sharing. pinch. Back in Nov '22, this 3rd Gen CAR-T...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $28.14K | 7.037M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 243067 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 14771167 | 22 |
View Market Depth
| Last trade - 15.39pm 20/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |